In a recent study, Chihara et al. revealed that continuous stimulation with TGF-β induces the robust phosphorylation of SMAD3, which subsequently induces an increase in the CD44+/CD24−/low population in different HER2+ BC cell lines, causing resistance to anti-HER2 drugs [99]. Here, ERBB2 is linked to breast cancer.